In addition, because of very high cardiovascular risk, CAD patients with diabetes mellitus should receive a sodium-glucose co-transporter 2 inhibitors or a glucagon-like peptide-1 receptor agonist (Cosentino et al., 2020). This evidence concerns the gene GLP1R and coronary artery disorder.